Pendopharm recalls seven lots of diphenhydramine capsules across Canada
Health Canada lists four lots of PDP-diphenhydramine 25 mg and three of 50 mg in a national retailer-level recall over an impurity that may exceed specifications.
In this article & details
Pendopharm is recalling seven lots of PDP-diphenhydramine capsules distributed across Canada after identifying an impurity that may exceed the product’s specifications. Health Canada posted the recall Nov. 9 and said it reaches retailers. It includes four lots of the 25 mg capsule and three lots of the 50 mg capsule. Health Canada recall notice
Which diphenhydramine lots are affected?
- 25 mg · DIN 00757683
- Lots 638997, 658003, 664380, 669604
- 50 mg · DIN 00757691
- Lots 653809, 658757, 664907
Health Canada identified the impurity as N-nitroso-N-desmethyl diphenhydramine and classified the action as a Type II recall. The agency linked an earlier Oct. 5 notice about the same impurity in a separate set of 25 mg lots. The November notice lists affected lots for both strengths. November lot list · October recall notice
Health Canada advises patients to check whether their lot is affected and speak to a healthcare provider before stopping an affected product or if they have health concerns. It directs questions about the recall to Pendopharm, a division of Pharmascience, and accepts reports of suspected side effects. Recall contacts and reporting instructions
References
- PDP-diphenhydramine 25 mg and 50 mg capsules recall — Health Canada, RA-82928, Nov. 9, 2026
- Earlier PDP-diphenhydramine 25 mg capsule recall — Health Canada, RA-82720, Oct. 5, 2026